von Tobias Borgers | Apr 6, 2021 | Roche
Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock...
von Tobias Borgers | Dez 13, 2020 | Roche
Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use Genomics insights generated through sequencing an individual’s DNA play a critical role in personalised healthcare and clinical diagnostics of the futureRoche is committed...
von Tobias Borgers | Sep 5, 2020 | Roche
FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer Basel, 19 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA)...
von Tobias Borgers | Mai 22, 2020 | Roche
Roche launches new blood gas digital solution designed to improve patient care Roche v-TAC is a new digital diagnostics solution that allows clinicians to obtain arterial blood gas values from patients in need of blood gas testing via a simpler, less painful and less...
von Tobias Borgers | Mai 21, 2020 | Roche
FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US Approval based on the...
von Tobias Borgers | Dez 1, 2019 | Roche
Media Release Basel, 04 September 2019 Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS Investigational medicine satralizumab significantly reduces the risk of relapse...
